Simulab to commercialize medical skill evaluation software developed by University of Washington’s BioRobotics Laboratory.
Simulab Corporation, a Seattle-based developer of medical and surgical simulators, is working with the BioRobotics Laboratory at the University of Washington to commercialize UW software capable of measuring hands-on surgical skills. Simulab plans to target surgical residency programs and large hospitals for the skill-evaluating simulators. In this Phase II project, UW will receive $89,811 in research and technology development funding from Washington Technology Center.
“This project will validate unique software deployed in the EDGE platform, developed by UW and licensed by Simulab, which tracks hand motions of medical personnel while they interact with model tissues and organs,” said professor Hannaford. “The technology quantitatively matches performance to level of skill.
“Simulab is thrilled with the second round of funding support from WTC. The commercialization of EDGE will be the culmination of a long-standing collaboration between the University of Washington and Simulab. There is nothing currently available on the market to objectively evaluate and validate surgical skills, so EDGE is a crucial addition to the medical training process and we excited to be a part of it.” said Christopher Toly, Chief Executive Officer and Chief Technology Officer of Simulab.
“As our economy continues to struggle, innovative private-public partnerships like this are imperative. By leveraging more resources, we will be able to put more Washington workers back to work in living wage jobs,” state Sen. Jeanne Kohl-Welles (D-Seattle) said.
“These advancements, happening as a result of creative visionaries, the University of Washington’s world class research departments, and Washington Technology Center’s tremendously important grants represent everything we are trying to accomplish in the biotech field,” said state Rep. Reuven Carlyle (D-Seattle). “The innovation, high paying jobs, R&D ripple effect and commercialization of knowledge will improve not just Seattle but the whole world. We have all of the central ingredients to make Seattle the world’s premier hub for life science, global health, R&D commercialization and other fields representative of science in the 21st Century.”
“This is a big win for the UW and Simulab that could have huge long-term medical and economic potential,” said state Rep. Mary Lou Dickerson (D-Seattle), who represents the Seattle community where Simulab is located.
About Simulab Corporation
About the Research & Technology Development (RTD) Grant Program
About Washington Technology Center